Identification of a 14kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis

Journal of Pharmaceutical and Biomedical Analysis

Volumn 78-79, Issue , 2013, Pages 45-51

  De Freitas Caires, Nathalie ^a,b,c,d   Legendre, Benjamin ^a,b,c   Parmentier, Erika ^e   Scherpereel, Arnaud ^a,b,c,e   Tsicopoulos, Anne ^a,b,c   Mathieu, Daniel ^e   Lassalle, Philippe ^a,b,c  

^a INSERM U1019   (France)

^b UNIV LILLE   (France)

^c CNRS   (France)

^d Lunginnov   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Biomarker; Cathepsin G; Endocan; Endothelium; Immunoassay; Sepsis

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN G; CELL PROTEIN; ENDOCAN; LEUKOCYTE ELASTASE; MYELOBLASTIN; UNCLASSIFIED DRUG; ESM1 PROTEIN, HUMAN; PROTEOGLYCAN; TUMOR PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DETERMINATION; SEPSIS; SEPTIC SHOCK; BLOOD; VALIDATION STUDY;

BIOLOGICAL MARKERS; CATHEPSIN G; HUMANS; NEOPLASM PROTEINS; PROTEOGLYCANS; SEPSIS;

EID: 84874549633     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.01.035     Document Type: Article

References (21)

1. Rangel-Frausto M.S., Pittet D., Costigan M., Hwang T., Davis C.S., Wenzel R.P. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995, 273:117-123.
2. Brun-Buisson C., Doyon F., Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am. J. Respir. Crit. Care Med. 1996, 154:617-624.
3. Brun-Buisson C., Meshaka P., Pinton P., Vallet B. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med. 2004, 30:580-588. EPISEPSIS Study Group.
4. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001, 29:1303-1310.
5. Ferreira F.L., Bota D.P., Bross A., Mélot C., Vincent J.L. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001, 286:1754-1758.
6. Slade E., Tamber P.S., Vincent J.L. The surviving sepsis campaign: raising awareness to reduce mortality. Crit. Care 2003, 7:1-2.
7. Aird W.C. Endothelium as a therapeutic target in sepsis. Curr. Drug Targets 2007, 4:501-507.
8. Lee W.L., Slutsky A.S. Sepsis and endothelial permeability. N. Engl. J. Med. 2010, 363:689-691.
9. Harrois A., Dupic L., Duranteau J. Targeting microcirculation in resuscitation of acutely unwell patients. Curr. Opin. Crit. Care 2011, 3:303-307.
10. Lassalle P., Molet S., Janin A., Van der Heyden J., Tavernier J., Fiers W., Devos R., Tonnel A.B. ESM-1 is a novel human endothelial cell specific molecule expressed in lung and regulated by cytokines. J. Biol. Chem. 1996, 271:20458-20464.
11. Béchard B., Gentina T., Delehedde M., Scherpereel A., Lyon M., Aumercier M., Vazeux R., Richet C., Kervoaze G., Degand P., Jude B., Janin A., Fernig D., Tonnel A.B., Lassalle P. Endocan is a novel chondroitin/dermatan sulfate proteoglycan which promotes hepatocyte growth factor/scatter factor mitogenic activity. J. Biol. Chem. 2001, 276:48341-48349.
12. Béchard D., Meignin V., Scherpereel A., Oudin S., Kervoaze G., Bertheau P., Janin A., Tonnel A.B., Lassalle P. Characterization of a secreted form of endothelial cell-specific molecule-1 (ESM-1) by specific monoclonal antibodies. J. Vasc. Res. 2000, 37:417-425.
13. Tsai J.C., Zhang J., Minami T., Voland C., Zhao S., Yi X., Lassalle P., Oettgen P., Aird W.C. Cloning and characterization of the human lung endothelial-cell-specific molecule-1 promoter. J. Vasc. Res. 2002, 39:148-159.
14. Scherpereel A., Depontieu F., Grigoriu B., Cavestri B., Tsicopoulos A., Gentina T., Jourdain M., Pugin J., Tonnel A.B., Lassalle P. Endocan a new endothelial marker in human sepsis. Crit. Care Med. 2006, 34:532-537.
15. Mikkelsen M.E., Shah C.V., Scherpereel A., Lanken P.N., Lassalle P., Bellamy S.L., Localio A.R., Albelda S.M., Meyer N.J., Christie J.D. Lower serum endocan levels are associated with the development of acute lung injury after major trauma. J. Crit. Care 2012, 27:522.e11-522.e17.
16. Depontieu F., de Freitas Caires N., Gourcerol D., Giordano J., Grigoriu B., Delehedde M., Lassalle P. Development of monoclonal antibodies and ELISA specific for the mouse vascular endocan. J. Immunol. Methods 2012, 378:88-94.
17. Feinberg M. Guide de validation des méthodes d'analyse, " in Labo-Stat" 2009, Editions TEC&DOC, Lavoisier.
18. Bone R.C., Sibbald W.J., Sprung C.L. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992, 101:148-153.
19. Adkison A.M., Raptis S.Z., Kelley D.G., Pham C.T. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J. Clin. Invest. 2002, 109:363-371.
20. Attucci S., Korkmaz B., Juliano L., Hazouard E., Girardin C., Brillard-Bourdet M., Rehault S., Anthonioz P., Gauthier F. Measurement of free and membrane-bound cathepsin G in human neutrophils using new sensitive fluorogenic substrates. Biochem. J. 2002, 366:965-970.
21. Rehault S., Brillard-Bourdet M., Juliano M.A., Juliano L., Gauthier F., Moreau T. New sensitive fluorogenic substrates for human cathepsin G based on the sequence of serpin-reactive site loops. J. Biol. Chem. 1999, 274:13810-13817.